Penn Capital Management Co. Inc. trimmed its holdings in shares of Intersect ENT, Inc. (NASDAQ:XENT) by 59.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,181 shares of the medical equipment provider’s stock after selling 39,515 shares during the quarter. Penn Capital Management Co. Inc. owned 0.09% of Intersect ENT worth $760,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. ClariVest Asset Management LLC bought a new stake in shares of Intersect ENT during the first quarter worth $148,000. Legal & General Group Plc lifted its position in shares of Intersect ENT by 3.8% during the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 255 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its position in shares of Intersect ENT by 109.1% during the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock worth $196,000 after purchasing an additional 6,000 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Intersect ENT during the second quarter worth $229,000. Finally, American International Group Inc. lifted its position in shares of Intersect ENT by 7.1% during the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock worth $269,000 after purchasing an additional 1,037 shares during the last quarter. Institutional investors and hedge funds own 83.12% of the company’s stock.

Intersect ENT, Inc. (NASDAQ XENT) opened at 29.75 on Friday. The stock’s market cap is $868.37 million. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $33.25. The stock’s 50 day moving average price is $30.56 and its 200 day moving average price is $24.46.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.11. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The company had revenue of $24.00 million during the quarter, compared to the consensus estimate of $22.62 million. During the same quarter in the prior year, the firm posted ($0.21) EPS. The firm’s quarterly revenue was up 24.4% on a year-over-year basis. On average, analysts forecast that Intersect ENT, Inc. will post ($0.61) earnings per share for the current year.

Several research firms have recently weighed in on XENT. Northland Securities reiterated a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a research report on Wednesday, August 2nd. Zacks Investment Research downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. BidaskClub downgraded Intersect ENT from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. TheStreet upgraded Intersect ENT from a “d” rating to a “c-” rating in a research report on Tuesday, August 1st. Finally, ValuEngine upgraded Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $27.11.

In other news, CFO Jeryl L. Hilleman sold 12,835 shares of the company’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $27.18, for a total transaction of $348,855.30. Following the completion of the sale, the chief financial officer now owns 27,835 shares of the company’s stock, valued at approximately $756,555.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Richard E. Kaufman sold 22,425 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $30.22, for a total transaction of $677,683.50. Following the sale, the chief operating officer now directly owns 149,821 shares of the company’s stock, valued at approximately $4,527,590.62. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 133,426 shares of company stock valued at $3,950,485. 13.70% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/intersect-ent-inc-xent-shares-sold-by-penn-capital-management-co-inc.html.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.